Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1731406 | 0.97 | F2R (0.40) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL5488726 | 0.87 | KDM4E (0.35) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL1732775 | 0.87 | F2R (0.43) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL1730405 | 0.86 | F2R (0.45) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL1731191 | 0.86 | F2R (0.39) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL1731401 | 0.85 | F2R (0.38) | F2RKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14449014 | 0.85 | F2R (0.45) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL1729002 | 0.85 | F2R (0.44) | F2RKDM4ENPC1MAPTRAB9A | |
| Trifluoroacetic Acid SCHEMBL1729292 | 0.84 | F2R (0.42) | F2RKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14449185 | 0.84 | F2R (0.44) | F2RKDM4ENPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988902-B1 | PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-23 | — | — | EP | claimed |
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | claimed |
| EP-0340010-A2 | Heterocyclic nitromethane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | claimed |
| EP-1988902-B1 | PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | disclosed |
| EP-0340010-A2 | Heterocyclic nitromethane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | SIGMAR1, OPRL1, OPRK1 | F2R 645/4885KDM4E 4592/4885NPC1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.